| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | ATGC INC | 3670 NORTHBROOK DR | SUPERIOR TOWNSHIP | MI | 48198-8704 | WASHTENAW | USA | R41GM149016 | Structure-based computational engineering of saCas9 PAM requirement | 000 | 1 | NIH | 4/28/2025 | $0 |
| | 2025 | 2023 | ATGC INC | 3670 NORTHBROOK DR | SUPERIOR TOWNSHIP | MI | 48198-8704 | WASHTENAW | USA | R42GM122181 | Novel methods to improve nuclease mediated homologous recombination | 000 | 3 | NIH | 4/29/2025 | $0 |
| | 2025 | 2022 | ATGC INC | 3670 NORTHBROOK DR | SUPERIOR TOWNSHIP | MI | 48198-8704 | WASHTENAW | USA | R41GM146516 | Rapid egg bioreactor construction for Fabry disease therapeutics | 000 | 1 | NIH | 11/18/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,215,282 ) |
| | 2023 | 2023 | ATGC INC | 540 AVIS DR | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R41GM149016 | Structure-based computational engineering of saCas9 PAM requirement | 000 | 1 | NIH | 3/13/2023 | $274,955 |
| | 2023 | 2023 | ATGC INC | 540 AVIS DR | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R42GM122181 | Novel methods to improve nuclease mediated homologous recombination | 000 | 3 | NIH | 5/1/2023 | $940,327 |
|
| Issue Date FY: 2022 ( Subtotal = $1,427,707 ) |
| | 2022 | 2022 | ATGC INC | 540 AVIS DRIVE, SUITE B | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R42GM122181 | Novel methods to improve nuclease mediated homologous recombination | 000 | 2 | NIH | 4/29/2022 | $854,843 |
| | 2022 | 2022 | ATGC INC | 540 AVIS DR | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R41GM146516 | Rapid egg bioreactor construction for Fabry disease therapeutics | 000 | 1 | NIH | 8/5/2022 | $259,520 |
| | 2022 | 2022 | ATGC INC | 540 AVIS DR | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R42GM122181 | Novel methods to improve nuclease mediated homologous recombination | 001 | 2 | NIH | 9/15/2022 | $313,344 |
| | 2022 | 2019 | ATGC INC | 540 AVIS DR | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R42TR001711 | A nanoparticle delivery system for CRISPR/Cas9 based therapeutics | 000 | 3 | NIH | 7/26/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | ATGC INC | 540 AVIS DRIVE, SUITE B | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R42TR001711 | A nanoparticle delivery system for CRISPR/Cas9 based therapeutics | 000 | 3 | NIH | 8/6/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | ATGC INC | 540 AVIS DRIVE, SUITE B | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R42TR001711 | A nanoparticle delivery system for CRISPR/Cas9 based therapeutics | 001 | 3 | NIH | 7/30/2020 | $0 |
| | 2020 | 2019 | ATGC INC | 540 AVIS DRIVE, SUITE B | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R42TR001711 | A nanoparticle delivery system for CRISPR/Cas9 based therapeutics | 000 | 3 | NIH | 11/21/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $732,982 ) |
| | 2019 | 2019 | ATGC INC | 540 AVIS DRIVE, SUITE B | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R42TR001711 | A nanoparticle delivery system for CRISPR/Cas9 based therapeutics | 000 | 3 | NIH | 9/7/2019 | $732,982 |
| | 2019 | 2017 | ATGC INC | 540 AVIS DRIVE, SUITE B | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R41GM122181 | Novel methods to improve nuclease mediated homologous recombination | 000 | 1 | NIH | 3/25/2019 | $0 |
| | 2019 | 2017 | ATGC INC | 540 AVIS DRIVE, SUITE B | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R41OD023245 | Ground state rabbit pluripotent stem cells | 000 | 1 | NIH | 5/20/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $749,563 ) |
| | 2018 | 2018 | ATGC INC | 401 W. MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R42TR001711 | A nanoparticle delivery system for CRISPR/Cas9 based therapeutics | 000 | 2 | NIH | 8/24/2018 | $749,563 |
| | 2018 | 2017 | ATGC INC | 540 AVIS DRIVE, SUITE B | ANN ARBOR | MI | 48108-7906 | WASHTENAW | USA | R42TR001711 | A nanoparticle delivery system for CRISPR/Cas9 based therapeutics | 001 | 1 | NIH | 9/17/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $675,750 ) |
| | 2017 | 2017 | ATGC INC | 401 W. MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R41OD023245 | Ground state rabbit pluripotent stem cells | 000 | 1 | NIH | 9/14/2017 | $165,736 |
| | 2017 | 2017 | ATGC INC | 401 W. MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R42TR001711 | A nanoparticle delivery system for CRISPR/Cas9 based therapeutics | 000 | 1 | NIH | 5/25/2017 | $225,000 |
| | 2017 | 2017 | ATGC INC | 401 W. MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R41OD023245 | Ground state rabbit pluripotent stem cells | 000 | 1 | NIH | 9/14/2017 | $60,014 |
| | 2017 | 2017 | ATGC INC | 401 W. MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R41GM122181 | Novel methods to improve nuclease mediated homologous recombination | 000 | 1 | NIH | 8/1/2017 | $225,000 |
|
|
